HK1101696A1 - Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent - Google Patents

Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Info

Publication number
HK1101696A1
HK1101696A1 HK07106570.8A HK07106570A HK1101696A1 HK 1101696 A1 HK1101696 A1 HK 1101696A1 HK 07106570 A HK07106570 A HK 07106570A HK 1101696 A1 HK1101696 A1 HK 1101696A1
Authority
HK
Hong Kong
Prior art keywords
derivative
monoclonal antibody
therapeutic agent
specifically binding
potential anti
Prior art date
Application number
HK07106570.8A
Other languages
English (en)
Inventor
Linda Gillian Durrant
Tina Parsons
Original Assignee
Cephalon Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32526936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1101696(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd
Publication of HK1101696A1 publication Critical patent/HK1101696A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK07106570.8A 2004-05-12 2007-06-20 Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent HK1101696A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410627.4A GB0410627D0 (en) 2004-05-12 2004-05-12 Specific binding members
PCT/GB2005/001805 WO2005108430A2 (en) 2004-05-12 2005-05-11 Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Publications (1)

Publication Number Publication Date
HK1101696A1 true HK1101696A1 (en) 2007-10-26

Family

ID=32526936

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07106570.8A HK1101696A1 (en) 2004-05-12 2007-06-20 Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Country Status (17)

Country Link
US (2) US7915387B2 (xx)
EP (3) EP2392598A1 (xx)
JP (2) JP4944016B2 (xx)
KR (1) KR101213282B1 (xx)
CN (1) CN1961004B (xx)
AU (2) AU2005240837B2 (xx)
BR (1) BRPI0510950A (xx)
CA (1) CA2563516C (xx)
ES (1) ES2400571T3 (xx)
GB (1) GB0410627D0 (xx)
HK (1) HK1101696A1 (xx)
IL (1) IL178791A (xx)
MX (1) MXPA06012955A (xx)
NO (1) NO20065651L (xx)
NZ (3) NZ593171A (xx)
WO (1) WO2005108430A2 (xx)
ZA (1) ZA200609365B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EA024695B1 (ru) 2009-03-16 2016-10-31 Сефалон Острэйлиа Пти Лтд. Гуманизированные антитела с противоопухолевой активностью
AU2010314798B2 (en) * 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
EP3131929B1 (en) * 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3464682D1 (en) 1983-05-09 1987-08-13 Gen Electric Co Plc Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
DK0628639T3 (da) * 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
UA41929C2 (uk) * 1994-03-17 2001-10-15 Мерк Патент Гмбх Анти-ефрр одноланцюжковий fv,молекула днк,яка його кодує, анти-ефрр антитіло,спосіб одержання анти-ефрр одноланцюжкового fv,спосіб одержання повного анти-ефрр антитіла та фармацевтична композиція (варіанти)
JPH09173063A (ja) 1995-12-26 1997-07-08 Cosmo Sogo Kenkyusho:Kk 抗ヒトリポタンパク質（ａ）モノクローナル抗体可変領域のＤＮＡ塩基配列およびアミノ酸配列
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
AU9262598A (en) 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
KR101213282B1 (ko) 2012-12-17
NZ550738A (en) 2011-03-31
JP2012105654A (ja) 2012-06-07
AU2011200487A1 (en) 2011-02-24
GB0410627D0 (en) 2004-06-16
IL178791A (en) 2012-07-31
US8343490B2 (en) 2013-01-01
US7915387B2 (en) 2011-03-29
CA2563516C (en) 2013-10-01
JP2008502324A (ja) 2008-01-31
US20080118509A1 (en) 2008-05-22
AU2011200487B2 (en) 2012-11-01
ZA200609365B (en) 2008-05-28
EP1745077A2 (en) 2007-01-24
WO2005108430A3 (en) 2006-04-27
EP2392598A1 (en) 2011-12-07
AU2005240837B2 (en) 2010-11-11
US20110212113A1 (en) 2011-09-01
MXPA06012955A (es) 2007-04-25
ES2400571T3 (es) 2013-04-10
EP1745077B1 (en) 2012-11-28
JP4944016B2 (ja) 2012-05-30
NZ593171A (en) 2012-08-31
KR20070085116A (ko) 2007-08-27
CA2563516A1 (en) 2005-11-17
NZ589214A (en) 2012-02-24
CN1961004A (zh) 2007-05-09
WO2005108430A2 (en) 2005-11-17
IL178791A0 (en) 2007-03-08
CN1961004B (zh) 2012-11-07
BRPI0510950A (pt) 2007-11-20
NO20065651L (no) 2007-02-06
AU2005240837A1 (en) 2005-11-17
EP2397500A1 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
IL191340A (en) Monoclonal antibodies against e8o
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
TWI366570B (en) Antibodies to madcam
IL179672A (en) Monoclonal antibodies against 3 cd human
HK1219488A1 (zh) 針對類活化素受體激酶- 之人類單株抗體
EP1658095A4 (en) ANTI-CD3 ANTIBODY DESIMMUNISE
EP1947178A4 (en) MONOCLONAL HUMAN ANTIBODY BINDING TO HUMAN GM-CSF AND ANTIGEN BINDING SITE OF THIS ANTIBODY
ZA200802051B (en) Anti-CD3 antibody formulations
IL189788A0 (en) Human monoclonal antibodies to cd70
ZA200607705B (en) Antibody calicheamicin conjugates
AU2003295411A8 (en) Human monoclonal antibodies to heparanase
ZA200706969B (en) Conjugation of Streptococcal capsular saccharides
IL179476A (en) Isolated antibody associated with IL-13, a medical preparation that includes it, a method of preparation and use thereof
HK1105126A1 (en) Monoclonal antibodies to progastrin
EP1766017A4 (en) TUMOR SPECIFIC ANTIBODY
IL186659A (en) Isolated monoclonal antibodies to 31il and their use as a remedy for scratching a mammal
ZA200802641B (en) Human monoclonal antibodies to CD70
EP1768999A4 (en) B7-DC BINDING ANTIBODY
HK1101696A1 (en) Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
GB0413868D0 (en) Dimensional anlaysis of saccharide conjugates
AU2003234706A8 (en) Antibodies that specifically bind to tl5
AU2003218456A1 (en) Antibodies that specifically bind to gmad
AU2003256299A8 (en) Antibodies that specifically bind to reg iv
EP1688433A4 (en) ANTIBODY COMPOSITION SPECIFICALLY INDUCING GANGLIOSIDE GM2
EP1712564A4 (en) MONOCLONAL ANTIBODY ANTI-NC1

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170511